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Summary.-To determine whether vindesine receptors are present in human leuk-
aemic cells, K562 cells (established from chronic myelogenous leukaemia in blastic
crisis) were incubated with 3H-vindesine. Binding of 3H-vindesine increased with
incubation time and with increase in number of K562 cells. However, when excessive
amounts of nonradioactive vindesine were added, the 3H-vindesine was displaced.
Binding of 3H-vindesine was only inhibited by vinblastine, vincristine and vindesine.
These results suggest that K562 cells have receptors for vindesine and that these
receptors are common to vinca alkaloids.
Scatchard analysis showed that the number of vindesine receptors differed accord-
ing to the kind of cells tested. K562 and a T-cell leukaemia-derived cell line, MOLT-4,
had more receptors than an acute promyelocytic leukaemia-derived cell line, HL-60,
and normal blood lymphocytes. The degree of vindesine affinity to receptors did not
differ markedly among the above-mentioned cells.
THE TREATMENT of certain types of
malignancies with vinca alkaloids reduces
the number of tumour cells. The effects of
the treatment, however, differ from dis-
ease to disease and even from case to case
in the same disease. The causes of the
difference are not known. Since it has been
shown that in hormonal therapy of breast
cancer the number of hormone receptors
may significantly influence the course of
the disease (Knight et al., 1977; McGuire,
1975), we speculated that the effects of
vinca alkaloids might depend on the
number of vinca-alkaloid receptors in the
tumour cells, or on their affinity to the
receptor site. As far as we know, detailed
studies have not been performed on viyca-
alkaloid receptors in human tumour cells,
nor on their clinical relevance.
A new vinca-alkaloid derivative, vinde-
sine, is currently under evaluation in
clinical cancer chemotherapy (Miller et al.,
1980; Stambaugh, 1980; Young, 1980).
The physiological mechanisms by which
vinca alkaloids kill cells in vivo and in vitro
are not clear. Since vinblastine and
vincristine are known to bind to tubulin
from brain (Owellen et al., 1972, 1974) or
HeLa cells (Marantz et al., 1969), the
major protein subunit of microtubules,
with high affinity and specificity, it has
been postulated that vinca alkaloids affect
the spindle microtubules during meta-
phase (Palmer et al., 1960; Cutts, 1961),
resulting in abnormal cytokinesis of the
cells, which causes multinucleated cells
and cell death (Chirife & Studzinski, 1978).
Recently, the interaction between tubulin
from a pig brain and vindesine was also
described (Owellen et al., 1977).
To ascertain whether vindesine recep-
tors were present in human tumour cells,
we used the following cell lines: K562, a
cell line established from the pleural
effusion of a patient with chronic myelo-
genous leukaemia in terminal blastic
crisis; MOLT-4, a cell line from a patient
with T-cell acute lymphoblastic leuk-
aemia; and HL-60, a cell line from a
patient with acute promyelocytic leuk-VINDESINE RECEPTORS IN K562
aemia. We selected the above cell lines
because it is well known that some
patients with lymphocytic leukaemia or
chronic mylogenous leukaemia in blastic
crisis respond to vinca-alkaloid therapy,
while patients with myelogenous leuk-
aemia are in general resistant to vinca-
alkaloid therapy.
MATERIALS AND METHODS
The K562 cells were the generous gift of
Dr G. Klein, Department ofTumour Biology,
Karolinska Institute, Stockholm, Sweden,
and the HL-60 cells were the generous gift
of Dr S. Sato, Department of Biochemistry,
National Cancer Centre Research Institute,
Tokyo, Japan. The cells were maintained in
our laboratory in RPMI 1640 (GIBCO,
Grand Island, N.Y.) supplemented with
100 u/ml of penicillin, 100 ,ug/ml of strepto-
mycin and 10% calf serum (Flow Lab.,
Virginia) in 60 x 15mm plastic dishes (Falcon
no. 3002, Oxnard, Calif.) at 37°C in a humidi-
fied atmosphere of 5% CO2. Normal blood
lymphocytes were separated with Ficoll-
Conray gradients from the heparinized peri-
pheral blood of a normal donor. Because
platelets are known to have vinca-alkaloid
receptors (Gout et al., 1978; Secret et al.,
1972), these were removed by centrifuging
x 3 at 600 g for 45 sec and the pellets were
used. Studies on the binding of the cultured
cells were performed during their log phase
of growth (2-3 days after reseeding in liquid
culture). After being washed twice with
phosphate-buffered saline (pH 7.4) contain-
ing 1% bovine serum albumin (PBS c BSA)
the cells were suspended at a density between
2 and 8x 106 cells/ml in PBS c BSA. Most
measurements of the binding were made at a
cell concentration of4 x 106 cells/ml. Aliquots
of0 3 ml ofthe cell suspension were delivered
into 12 x 105mm glass test tubes (Pyrex and
Iwaki Glass, Tokyo) and incubated at 37°C
with 0-123 juCi of 3H-vindesine (sp. act.
4.7 Ci/mmol, 5-6 mCi/mg, Radiochemical
Centre, Amersham, U.K.) with or without
200-fold unlabelled vindesine (10-5M). The
residual binding in the presence of non-
radioactive vindesine was assumed to repre-
sent nonspecific binding, and the difference
between the total binding of 3H-vindesine
and this nonspecific binding was taken to be
specific binding of vindesine. At the end of
the incubation period, 6 ml of cold PBS c
BSA was rapidly added to each tube and the
cells were washed x 3 with PBS a BSA. The
cell pellets were then dissolved with 0-6 ml
of Protosol (New England Nuclear, Boston),
to which 10 ml of liquid scintillator (ACS II,
Radiochemical Centre, Amersham, U.K.)
was added. This solution was transferred to
liquid scintillation vials, and its radioactivity
was counted by a liquid scintillation counter.
In order to determine the specificity of
vindesine receptor in K562 cells, other
unlabelled antileukaemic agents such as
vincristine, vinblastine, cytosine arabinoside,
daunorubicin or 6MP-ribose were added
with 3H-vindesine.
RESULTS
K562 cells, 1-2 x 106, were incubated at
37°C with 0-123 ,uCi of 3H-vindesine for
various lengths of time (Fig. 1). Binding of
3H-vindesine increased with incubation
time, and reached a plateau at 4-6 h.
When 200-fold excess of nonradioactive
vindesine was added as a chaser after
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FIG. 1.-Time course of 3H-vindesine binding
in K562 cells. Aliquots of K562 cells (1-2 x
106 cells/tube) were incubated at 370C with
3H-vindesine in the presence (0 O)
and absence (0 0*) of an excess of
unlabelled vindesine (10-5M). At intervals,
samples were taken from the suspension to
determine the amount ofvindesine binding
to the K562 cells. After 2h incubation, an
excess of unlabelled vindesine (10-5M) was
added to each tube, and the radioactivity
retained by K562 cells (0-- --0) on
further incubation was determined at 4 h
and 6 h.
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FIG. 2.-Dose relationship between the
number of cells and specific activity.
Various numbers of K562 cells were in-
cubated with 3H-vindesine for 4 h. The
ordinate indicates the difference between
the total binding of 3H-vindesine and the
nonspecific binding.
3H-Vindesine binding increased as the
number of cells increased (Fig. 2).
In Fig. 3, the specificity of the vinca-
alkaloid receptor binding was investigated
by testing the ability of the various
unlabelled agents to compete with 3H-
vindesine for vinca-alkaloid binding sites.
The binding of3H-vindesine was competi-
tively blocked by the addition of various
amounts of unlabelled vindesine, vincrist-
ine or vinblastine. The above 3 agents
displayed virtually the same degree of
inhibition. The same concentrations of
daunorubicin, cytosine arabinoside and
6MP-ribose, however, did not block the
binding of 3H-vindesine (Fig. 4).
Scatchard analysis was performed to
determine the number of vindesine recep-
tors in K562, MOLT-4 and HL-60 cells,
and normal blood lymphocytes. The above
cells had vindesine receptors of 4.9 x 106,
6-3 x 106, 3-4 x 106 and 1.5 x 106 sites/cell,









2xi0-8 2x10-7 2X10-6 2X10-5
concentration of drugs (M)
FIG. 3.-Inhibition of 3H-vindesine binding
by vinca alkaloids. K562 cells (1-2 x
106 cells/tube) were incubated with both
3H-vindesine (5 x 10-8M), and the indicated
dose of the following unlabelled vinca-
alkaloid derivatives for 4 h at 37'C: vinde-
sine, 0 *; vinblastine, 0 O; vin-
cristine, x x.
4-2 x 10-7M, 4-8 x 10-7M, 4.5 x 10-7M and
3.3 x 10-7M, respectively (Fig. 5).
DISCUSSION
The results of this study suggested that
K562 cells have receptors for vindesine,
since the binding of 3H-vindesine to K562
cells increased with incubation time (Fig.
1) and with increase in the number of
K562 cells (Fig. 2), and because this
binding was reversible (Fig. 1). The
binding of 3H-vindesine was inhibited by
vinblastine and vincristine to almost the
same degree with vindesine (Fig. 3) and
was not inhibited by agents other than
vinca alkaloids (Fig. 4), suggesting that
K562 cells have common receptors for
these vinca alkaloids.
Vinca alkaloids are cell-cycle-specific
agents. According to previous studies on
vinblastine and vincristine, they bind
specifically to the protein tubulin from pig
or rat brain, a key component of micro-
tubules (Marantz et al., 1969; Owellen et
fI
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FIG. 4.-Specificity of vindesine binding to
K562 cells. K562 cells (1-2 x 106 cells/tube
were incubated with both 3H-vindesine
(5X 10-8M) and the indicated doses of
antitumour agents other than vinca alka-
loid for 4 h at 370C: vindesine, 0;
6MP-ribose, OI; daunorubicin,
x x; cytosine arabinoside, A/ A.
al., 1972, 1974). Indeed, it was demon-
strated that tubulin is a receptor for
vinblastine and vincristine (Wilson et al.,
1974). Since the binding of vinblastine to
tubulin from pig brain was displaced by
vindesine according to Owellen et al.
(1977), and the present data (Fig. 3)
indicate the similarity of the binding sites
among vinblastine, vincristine and vin-
desine, it is possible that tubulin is a
receptor for vindesine as well.
Vinca alkaloids are widely used for the
treatment of malignant diseases, par-
ticularly of lymphoid neoplasms. Some
patients with lymphocytic leukaemia or
with blastic crisis of chronic myelogenous
leukaemia are resistant to them. It is
open to question whether the different
pharmacological effects result from the
difference in the vinca-alkaloid receptors
presentinthetumour cells. Amonghaemo-
poietic cells, only platelets are known to
bound, X10-'2 mole
FIG. 5.-Scatchardplots of thebinding curves
of each cell line and normal lymphocytes.
Cells of each cell line or normal lympho-
cytes (1.2 x 106) were incubated for 4 h at
370C with 3H-vindesine (5 x 10-8M) and
varying concentrations ofunlabelled vinde-
sine (2 x 10-8M to 2 x 10-5M).
have receptors for vincristine and vin-
blastine (Gout et al., 1978; Secret et al.,
1972). As far as we know, however,
haemopoietic tumour cells in humans have
never been investigated for receptors of
vinca alkaloids. Our results demonstrate
that the number ofvindesine receptor sites
differ from cell line to cell line, though the
affinity does not markedly differ. It is
interesting that MOLT-4 cells, established
from acute lymphocytic leukaemia, and
K562 cells, established from blastic crisis
of chronic myelogenous leukaemia, had
more receptor sites than HL-60 cells,
established from acute promyelocytic
leukaemia and normal blood lymphocytes.
It remains to be determined, however,
whether thedifference in the number of re-
ceptor sites could explain the difference in
clinical response to ynca alkaloids. We are
nowstudyingwhether cellsfrom leukaemic
patients have vinca-alkaloid receptors and
whether the presence of receptors is relev-
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